Showing 1921-1930 of 3163 results for "".
- CHMP Recommends Adtralza (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe ADhttps://practicaldermatology.com/news/chmp-recommends-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-ad/2461351/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending extending the approval of LEO Pharma’s Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- Paul Navarre Joins LEO Pharma’s Board of Directorshttps://practicaldermatology.com/news/paul-navarre-joins-leo-pharmas-board-of-directors/2461324/Paul Navarre is the newest member of LEO Pharma’s Board of Directors. Mr. Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies
- La Roche-Posay Becomes the First-Ever Official Sunscreen of the US Openhttps://practicaldermatology.com/news/la-roche-posay-becomes-the-first-ever-official-sunscreen-of-the-us-open/2461314/La Roche-Posay is the official sunscreen partner of the US Open. Beginning with this year's US Open, La Roche-Posay will have a sun safety education booth in the South Plaza of the USTA Billie Jean King National Tennis Center, with two additional product sampling kiosks on the
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formula
- Arcutis Completes Enrollment in Pivotal Phase 3 Roflumilast AD Trialhttps://practicaldermatology.com/news/arcutis-completes-enrollment-in-pivotal-phase-3-roflumilast-ad-trial/2461290/Arcutis Biotherapeutics, Inc. has completed enrollment of the last subject in its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria